SAN ANTONIO--(BUSINESS WIRE)--Azaya Therapeutics, Inc. announced today that it has been selected by the National Cancer Institute (NCI) for a research collaboration to study Azaya’s lead cancer therapy, ATI – 1123. The research will be conducted by the NCI’s Nanotechnology Characterization Laboratory (NCL), part of a major program, the Alliance for Nanotechnology in Cancer, to advance the medical applications of nanotechnology. The initial NCL efforts will focus on the characterization of Azaya’s product for its absorption, distribution and toxicity properties in both in vitro and in vivo studies.
